Machine Medicine: The Bonus Report Decoded

“Machine Medicine, three stocks leading the AI drug revolution” is the health-care report in Dr. Mark Skousen and Matt McCall’s “XAI Boom” bundle, and it is the campaign’s fourth act: the growth mechanism after the macro timing, the “second IPO” backdoors, and the private power boom. If you searched the phrase, here is what the presentation actually claims about AI drug discovery, what verifies, and our honest read of the report’s place in the bundle. The complete campaign treatment is our XAI Boom review.

What the Pitch Claims

The presentation’s drug-discovery framing: “There’s about 175 drugs that have been discovered by artificial intelligence that are ready in human trials.” The anchor story: “Last year, a drug that was invented by artificial intelligence went into human trials. At the highest dose, patients’ lung function didn’t just stop getting worse, it actually improved. That’s a first in medical history.”

Our review verified the anchor: it matches Insilico Medicine’s documented Phase 2 results for its AI-discovered pulmonary fibrosis drug, where the highest dose group showed lung-function improvement, a genuine first for an AI-designed molecule. The 175-drug figure is consistent with industry trackers of AI-discovered molecules in clinical pipelines, and the framing, that AI has moved from discovery tools to discovered drugs, is the fair version of the trend.

The report itself, “Machine Medicine, three stocks leading the AI drug revolution,” carries three gated names behind the subscription, with no fingerprints given in the free presentation, which is thinner sourcing than the campaign’s other reports (the power report at least has its sector facts on camera, and the second-IPO report has its company fingerprint).

Why AI Medicine Is the Fourth Act

The campaign’s structure is a layered argument, and machine medicine is the growth layer. Skousen’s macro act (the Gross Output swing “from negative 0.5% to positive 1.7% in a single quarter”) times the market; McCall’s second-IPO mechanism owns the AI labs’ re-rating; the private power boom owns the build-out’s hardware; and machine medicine owns the application layer where AI’s value shows up in revenue that is not capex.

The drug-discovery angle has a genuinely different risk profile from the rest of the bundle, worth understanding before buying: biotech milestones (trial results, approvals) are binary events on their own calendar, mostly independent of the AI trade’s sentiment cycle, so the three names would diversify the bundle’s pure-AI exposure if they are platform companies, and concentrate it further if they are AI-narrative biotechs. The free presentation does not tell you which, which is the report’s real contents question.

The Honest Read

What checks out: the Insilico Phase 2 story is real and remarkable, the clinical-pipeline scale is in the right range, and the trend from AI-as-tool to AI-as-inventor is the correct frame. McCall’s track-record block on health care has real names in it, Teladoc “gains as high as 527%,” with the genre’s rarest credential: the volunteered losses, “two of them did go bankrupt, Kodak and General Motors… But in that same $20 basket was AMD, at the time trading around $2.”

The caveats. The three names are gated with no fingerprints, so the free presentation’s drug act is thesis-only. The “175 drugs ready in human trials” phrasing compresses a pipeline that spans early Phase 1 to late-stage, with historical attrition rates intact: most molecules fail, AI-designed or not, and the “first in medical history” milestone is one trial’s readout, not a category guarantee. And drug-development timelines do not fit the campaign’s boom framing: the macro act says “the bigger the boom, the bigger the bust,” and medicine’s clock runs years past any market cycle.

For the bundle’s other acts: the SK Telecom free pick, the private power boom, and the second IPO concept are each covered in depth, and the Oxford Club publisher profile frames the campaign in the house’s week.

Frequently Asked Questions

Is the Insilico story real? Yes. The pitch’s anchor, “Last year, a drug that was invented by artificial intelligence went into human trials. At the highest dose, patients’ lung function didn’t just stop getting worse, it actually improved. That’s a first in medical history,” matches Insilico Medicine’s documented Phase 2 results for its AI-discovered pulmonary fibrosis drug. It is a genuine first for an AI-designed molecule.

What about the 175-drug figure? “There’s about 175 drugs that have been discovered by artificial intelligence that are ready in human trials” is consistent with industry trackers of AI-discovered molecules in clinical pipelines. The honest reading: “ready in human trials” compresses a pipeline that spans early Phase 1 to late-stage, and historical attrition rates apply to AI-designed molecules the same as any others. Most candidates fail.

Which three stocks does the report name? None in the free presentation. “Machine Medicine, three stocks leading the AI drug revolution” carries three gated names with no fingerprints, thinner sourcing than the campaign’s other reports (the power report has its sector facts on camera, the second-IPO report its company fingerprint).

What does this mean? The drug act diversifies the bundle’s pure-AI exposure only if the names are platform companies rather than AI-narrative biotechs, and the free pitch does not tell you which. Medicine’s clock also runs years past any market cycle, which is worth holding against the campaign’s boom framing (“the bigger the boom, the bigger the bust”) before buying the whole thesis.

The Offer

The bundle: a year each of The Skousen Report and McCall’s Innovation Report, “The Second IPO Blueprint,” “Machine Medicine,” the Private Power Boom report, the final exit plan service, and The Maxims of Wall Street, at “$795… for just $129” with 90 days to examine everything, a full refund, and every report kept. If the machine-medicine act is what earned your attention, the full presentation is here.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.